APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bioengineered Protein Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Bioengineered Protein Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchBioengineered Protein Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Bioengineered Protein Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Bioengineered Protein Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bioengineered Protein Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Bioengineered Protein Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Bioengineered Protein Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Bioengineered Protein Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Bioengineered Protein Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bioengineered Protein Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Bioengineered Protein Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Bioengineered Protein Drugs include Amoytop Biotech, Dr.Reddy’s, Fresenius, Hualan Bio, Panacea Biotech, ProBioGen, Reliance Life Sciences, Shanghai United Cell Biotechnology and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Bioengineered Protein Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Bioengineered Protein Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Bioengineered Protein Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bioengineered Protein Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Bioengineered Protein Drugs Segment by Company

Amoytop Biotech

Dr.Reddy’s

Fresenius

Hualan Bio

Panacea Biotech

ProBioGen

Reliance Life Sciences

Shanghai United Cell Biotechnology

GlaxoSmithKline

Eli Lilly

Roche

Merck

Novartis

Sanofi

Bioengineered Protein Drugs Segment by Type

Therapeutic Proteins

Vaccines

Monoclonal Antibodies

Bioengineered Protein Drugs Segment by Application

Autoimmune Disorder

Diabetes

Neurodegenerative

Infectious Disease

Cancer

Others

Bioengineered Protein Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bioengineered Protein Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bioengineered Protein Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bioengineered Protein Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bioengineered Protein Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Bioengineered Protein Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Bioengineered Protein Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Bioengineered Protein Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Bioengineered Protein Drugs Industry Trends Table 2. Bioengineered Protein Drugs Industry Drivers Table 3. Bioengineered Protein Drugs Industry Opportunities and Challenges Table 4. Bioengineered Protein Drugs Industry Restraints Table 5. Global Bioengineered Protein Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Bioengineered Protein Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Bioengineered Protein Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Bioengineered Protein Drugs Sales Market Share by Manufacturers Table 9. Global Bioengineered Protein Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Bioengineered Protein Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Bioengineered Protein Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Bioengineered Protein Drugs Manufacturers, Product Type & Application Table 13. Global Bioengineered Protein Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Bioengineered Protein Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Therapeutic Proteins Table 17. Major Manufacturers of Vaccines Table 18. Major Manufacturers of Monoclonal Antibodies Table 19. Global Bioengineered Protein Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Bioengineered Protein Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global Bioengineered Protein Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global Bioengineered Protein Drugs Sales Market Share by Type (2021-2026) Table 23. Global Bioengineered Protein Drugs Sales Market Share by Type (2027-2032) Table 24. Global Bioengineered Protein Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Bioengineered Protein Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global Bioengineered Protein Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global Bioengineered Protein Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Bioengineered Protein Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Autoimmune Disorder Table 30. Major Manufacturers of Diabetes Table 31. Major Manufacturers of Neurodegenerative Table 32. Major Manufacturers of Infectious Disease Table 33. Major Manufacturers of Cancer Table 34. Major Manufacturers of Others Table 35. Global Bioengineered Protein Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Bioengineered Protein Drugs Sales by Application (2021-2026) & (K Units) Table 37. Global Bioengineered Protein Drugs Sales by Application (2027-2032) & (K Units) Table 38. Global Bioengineered Protein Drugs Sales Market Share by Application (2021-2026) Table 39. Global Bioengineered Protein Drugs Sales Market Share by Application (2027-2032) Table 40. Global Bioengineered Protein Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Bioengineered Protein Drugs Revenue by Application (2021-2026) & (K Units) Table 42. Global Bioengineered Protein Drugs Revenue by Application (2027-2032) & (K Units) Table 43. Global Bioengineered Protein Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Bioengineered Protein Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Bioengineered Protein Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Bioengineered Protein Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global Bioengineered Protein Drugs Sales Market Share by Region (2021-2026) Table 48. Global Bioengineered Protein Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Bioengineered Protein Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units) Table 52. North America Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units) Table 53. Europe Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units) Table 55. Europe Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Bioengineered Protein Drugs Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Bioengineered Protein Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global Bioengineered Protein Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Bioengineered Protein Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Bioengineered Protein Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Bioengineered Protein Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Bioengineered Protein Drugs Revenue Market Share by Region (2027-2032) Table 67. Amoytop Biotech Company Information Table 68. Amoytop Biotech Business Overview Table 69. Amoytop Biotech Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Amoytop Biotech Bioengineered Protein Drugs Product Portfolio Table 71. Amoytop Biotech Recent Development Table 72. Dr.Reddy’s Company Information Table 73. Dr.Reddy’s Business Overview Table 74. Dr.Reddy’s Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Dr.Reddy’s Bioengineered Protein Drugs Product Portfolio Table 76. Dr.Reddy’s Recent Development Table 77. Fresenius Company Information Table 78. Fresenius Business Overview Table 79. Fresenius Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Fresenius Bioengineered Protein Drugs Product Portfolio Table 81. Fresenius Recent Development Table 82. Hualan Bio Company Information Table 83. Hualan Bio Business Overview Table 84. Hualan Bio Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Hualan Bio Bioengineered Protein Drugs Product Portfolio Table 86. Hualan Bio Recent Development Table 87. Panacea Biotech Company Information Table 88. Panacea Biotech Business Overview Table 89. Panacea Biotech Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Panacea Biotech Bioengineered Protein Drugs Product Portfolio Table 91. Panacea Biotech Recent Development Table 92. ProBioGen Company Information Table 93. ProBioGen Business Overview Table 94. ProBioGen Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. ProBioGen Bioengineered Protein Drugs Product Portfolio Table 96. ProBioGen Recent Development Table 97. Reliance Life Sciences Company Information Table 98. Reliance Life Sciences Business Overview Table 99. Reliance Life Sciences Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Reliance Life Sciences Bioengineered Protein Drugs Product Portfolio Table 101. Reliance Life Sciences Recent Development Table 102. Shanghai United Cell Biotechnology Company Information Table 103. Shanghai United Cell Biotechnology Business Overview Table 104. Shanghai United Cell Biotechnology Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Shanghai United Cell Biotechnology Bioengineered Protein Drugs Product Portfolio Table 106. Shanghai United Cell Biotechnology Recent Development Table 107. GlaxoSmithKline Company Information Table 108. GlaxoSmithKline Business Overview Table 109. GlaxoSmithKline Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. GlaxoSmithKline Bioengineered Protein Drugs Product Portfolio Table 111. GlaxoSmithKline Recent Development Table 112. Eli Lilly Company Information Table 113. Eli Lilly Business Overview Table 114. Eli Lilly Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Eli Lilly Bioengineered Protein Drugs Product Portfolio Table 116. Eli Lilly Recent Development Table 117. Roche Company Information Table 118. Roche Business Overview Table 119. Roche Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Roche Bioengineered Protein Drugs Product Portfolio Table 121. Roche Recent Development Table 122. Merck Company Information Table 123. Merck Business Overview Table 124. Merck Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Merck Bioengineered Protein Drugs Product Portfolio Table 126. Merck Recent Development Table 127. Novartis Company Information Table 128. Novartis Business Overview Table 129. Novartis Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Novartis Bioengineered Protein Drugs Product Portfolio Table 131. Novartis Recent Development Table 132. Sanofi Company Information Table 133. Sanofi Business Overview Table 134. Sanofi Bioengineered Protein Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Sanofi Bioengineered Protein Drugs Product Portfolio Table 136. Sanofi Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Bioengineered Protein Drugs Distributors List Table 140. Bioengineered Protein Drugs Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Bioengineered Protein Drugs Product Image Figure 2. Global Bioengineered Protein Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bioengineered Protein Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Bioengineered Protein Drugs Sales (2021-2032) & (K Units) Figure 5. Global Bioengineered Protein Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Bioengineered Protein Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Therapeutic Proteins Image Figure 9. Vaccines Image Figure 10. Monoclonal Antibodies Image Figure 11. Global Bioengineered Protein Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Bioengineered Protein Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Bioengineered Protein Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Bioengineered Protein Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Bioengineered Protein Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Bioengineered Protein Drugs Revenue Market Share by Type (2021-2032) Figure 17. Autoimmune Disorder Image Figure 18. Diabetes Image Figure 19. Neurodegenerative Image Figure 20. Infectious Disease Image Figure 21. Cancer Image Figure 22. Others Image Figure 23. Global Bioengineered Protein Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Bioengineered Protein Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Bioengineered Protein Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Bioengineered Protein Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Bioengineered Protein Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Bioengineered Protein Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Bioengineered Protein Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Bioengineered Protein Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Bioengineered Protein Drugs Sales Market Share by Country (2021-2032) Figure 43. China Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Bioengineered Protein Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Bioengineered Protein Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Bioengineered Protein Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Bioengineered Protein Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Bioengineered Protein Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Bioengineered Protein Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Bioengineered Protein Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Bioengineered Protein Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Bioengineered Protein Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Bioengineered Protein Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutic Proteins
  • Vaccines
  • Monoclonal Antibodies
Applications
  • Autoimmune Disorder
  • Diabetes
  • Neurodegenerative
  • Infectious Disease
  • Cancer
  • Others
Companies covered
  • Amoytop Biotech
  • Dr.Reddy’s
  • Fresenius
  • Hualan Bio
  • Panacea Biotech
  • ProBioGen
  • Reliance Life Sciences
  • Shanghai United Cell Biotechnology
  • GlaxoSmithKline
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Bioengineered Protein Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Bioengineered Protein Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Bioengineered Protein Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Bioengineered Protein Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Bioengineered Protein Drugs Market Dynamics
  1. 2.1 Bioengineered Protein Drugs Industry Trends
  2. 2.2 Bioengineered Protein Drugs Industry Drivers
  3. 2.3 Bioengineered Protein Drugs Industry Opportunities and Challenges
  4. 2.4 Bioengineered Protein Drugs Industry Restraints
3 Bioengineered Protein Drugs Market by Manufacturers
  1. 3.1 Global Bioengineered Protein Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Bioengineered Protein Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Bioengineered Protein Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Bioengineered Protein Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Bioengineered Protein Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Bioengineered Protein Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Bioengineered Protein Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Bioengineered Protein Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Bioengineered Protein Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Bioengineered Protein Drugs Tier 1, Tier 2, and Tier 3
4 Bioengineered Protein Drugs Market by Type
  1. 4.1 Bioengineered Protein Drugs Type Introduction
  2. 4.1.1 Therapeutic Proteins
  3. 4.1.2 Vaccines
  4. 4.1.3 Monoclonal Antibodies
  5. 4.2 Global Bioengineered Protein Drugs Sales by Type
  6. 4.2.1 Global Bioengineered Protein Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Bioengineered Protein Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Bioengineered Protein Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Bioengineered Protein Drugs Revenue by Type
  10. 4.3.1 Global Bioengineered Protein Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Bioengineered Protein Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Bioengineered Protein Drugs Revenue Market Share by Type (2021-2032)
5 Bioengineered Protein Drugs Market by Application
  1. 5.1 Bioengineered Protein Drugs Application Introduction
  2. 5.1.1 Autoimmune Disorder
  3. 5.1.2 Diabetes
  4. 5.1.3 Neurodegenerative
  5. 5.1.4 Infectious Disease
  6. 5.1.5 Cancer
  7. 5.1.6 Others
  8. 5.2 Global Bioengineered Protein Drugs Sales by Application
  9. 5.2.1 Global Bioengineered Protein Drugs Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Bioengineered Protein Drugs Sales by Application (2021-2032)
  11. 5.2.3 Global Bioengineered Protein Drugs Sales Market Share by Application (2021-2032)
  12. 5.3 Global Bioengineered Protein Drugs Revenue by Application
  13. 5.3.1 Global Bioengineered Protein Drugs Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Bioengineered Protein Drugs Revenue by Application (2021-2032)
  15. 5.3.3 Global Bioengineered Protein Drugs Revenue Market Share by Application (2021-2032)
6 Global Bioengineered Protein Drugs Sales by Region
  1. 6.1 Global Bioengineered Protein Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Bioengineered Protein Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Bioengineered Protein Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Bioengineered Protein Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Bioengineered Protein Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Bioengineered Protein Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Bioengineered Protein Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Bioengineered Protein Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Bioengineered Protein Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Bioengineered Protein Drugs Revenue by Region
  1. 7.1 Global Bioengineered Protein Drugs Revenue by Region
  2. 7.1.1 Global Bioengineered Protein Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Bioengineered Protein Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Bioengineered Protein Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Bioengineered Protein Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Bioengineered Protein Drugs Revenue (2021-2032)
  8. 7.2.2 North America Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Bioengineered Protein Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Bioengineered Protein Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Bioengineered Protein Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Bioengineered Protein Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amoytop Biotech
  2. 8.1.1 Amoytop Biotech Company Information
  3. 8.1.2 Amoytop Biotech Business Overview
  4. 8.1.3 Amoytop Biotech Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amoytop Biotech Bioengineered Protein Drugs Product Portfolio
  6. 8.1.5 Amoytop Biotech Recent Developments
  7. 8.2 Dr.Reddy’s
  8. 8.2.1 Dr.Reddy’s Company Information
  9. 8.2.2 Dr.Reddy’s Business Overview
  10. 8.2.3 Dr.Reddy’s Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dr.Reddy’s Bioengineered Protein Drugs Product Portfolio
  12. 8.2.5 Dr.Reddy’s Recent Developments
  13. 8.3 Fresenius
  14. 8.3.1 Fresenius Company Information
  15. 8.3.2 Fresenius Business Overview
  16. 8.3.3 Fresenius Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Bioengineered Protein Drugs Product Portfolio
  18. 8.3.5 Fresenius Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Bioengineered Protein Drugs Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 Panacea Biotech
  26. 8.5.1 Panacea Biotech Company Information
  27. 8.5.2 Panacea Biotech Business Overview
  28. 8.5.3 Panacea Biotech Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Panacea Biotech Bioengineered Protein Drugs Product Portfolio
  30. 8.5.5 Panacea Biotech Recent Developments
  31. 8.6 ProBioGen
  32. 8.6.1 ProBioGen Company Information
  33. 8.6.2 ProBioGen Business Overview
  34. 8.6.3 ProBioGen Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProBioGen Bioengineered Protein Drugs Product Portfolio
  36. 8.6.5 ProBioGen Recent Developments
  37. 8.7 Reliance Life Sciences
  38. 8.7.1 Reliance Life Sciences Company Information
  39. 8.7.2 Reliance Life Sciences Business Overview
  40. 8.7.3 Reliance Life Sciences Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Reliance Life Sciences Bioengineered Protein Drugs Product Portfolio
  42. 8.7.5 Reliance Life Sciences Recent Developments
  43. 8.8 Shanghai United Cell Biotechnology
  44. 8.8.1 Shanghai United Cell Biotechnology Company Information
  45. 8.8.2 Shanghai United Cell Biotechnology Business Overview
  46. 8.8.3 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai United Cell Biotechnology Bioengineered Protein Drugs Product Portfolio
  48. 8.8.5 Shanghai United Cell Biotechnology Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Bioengineered Protein Drugs Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Bioengineered Protein Drugs Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Roche Bioengineered Protein Drugs Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Merck Bioengineered Protein Drugs Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 Novartis
  74. 8.13.1 Novartis Company Information
  75. 8.13.2 Novartis Business Overview
  76. 8.13.3 Novartis Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Novartis Bioengineered Protein Drugs Product Portfolio
  78. 8.13.5 Novartis Recent Developments
  79. 8.14 Sanofi
  80. 8.14.1 Sanofi Company Information
  81. 8.14.2 Sanofi Business Overview
  82. 8.14.3 Sanofi Bioengineered Protein Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sanofi Bioengineered Protein Drugs Product Portfolio
  84. 8.14.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Bioengineered Protein Drugs Value Chain Analysis
  2. 9.1.1 Bioengineered Protein Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Bioengineered Protein Drugs Production Mode & Process
  6. 9.2 Bioengineered Protein Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Bioengineered Protein Drugs Distributors
  9. 9.2.3 Bioengineered Protein Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst